EnPlusOne Biosciences is a high-potential Series B biotechnology company (approx. $46M raised) spun out of the Wyss Institute at Harvard. Their ezRNA™ platform addresses a critical bottleneck in RNA therapeutics manufacturing. However, the project submission itself was of extremely low quality, containing hallucinated tags ('film') and false traction claims ('most people have used my product'). The score reflects the high real-world value and capital backing of the actual company, severely penalized by the poor response quality and lack of substantiated user reach in the provided text.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline